Showing 6881-6890 of 9462 results for "".
- AbbVie Awards 45 Scholarships to U.S. Students Living With Psoriasis, Eczema, and Other Chronic, Immune-Mediated Diseaseshttps://practicaldermatology.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-psoriasis-eczema-and-other-chronic-immune-mediated-diseases/2461970/AbbVie announced the 2023-2024 class of
- POCN Launches AD Center of Excellencehttps://practicaldermatology.com/news/pocn-launches-ad-center-of-excellence/2461965/
- FUE Technique Shows Promise for Treating Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/fue-technique-shows-promise-for-treating-acne-keloidalis-nuchae/2461963/Follicular unit excision (FUE) may help treat acne keloidalis nuchae (AKN), according to research in the Journal of The American Academy of Dermatology – JAAD Case Reports.
- The Dermatology Foundation, Skin of Color Society Partner to Offer Sanofi-Regeneron DEI Mid-Career Awardhttps://practicaldermatology.com/news/the-dermatology-foundation-skin-of-color-society-partner-to-offer-sanofi-regeneron-dei-mid-career-award/2461952/The Dermatology Foundation (DF) and the
- Sentient’s Tixel Receives FDA Nod for Treatment of Periorbital Wrinkleshttps://practicaldermatology.com/news/sentients-tixel-receives-fda-nod-for-treatment-of-periorbital-wrinkles/2461945/The device combines heat with the forward motion of a medical-grade titanium tip. The U.S. Food and Drug Administration has approved
- Bristol Myers Squibb’s New Sotyktu Campaign Reveals the Plain Truth About Living With Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibbs-new-clear-understanding-campaign-reveals-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2461914/Bristol Myers Squibb is rolling
- Merck, Moderna Initiate Phase 3 Study of V940-KEYTRUDA Combo for Adjuvant Treatment of Resected High-risk Melanomahttps://practicaldermatology.com/news/merck-moderna-initiate-phase-3-study-of-v940-mrna-4157-in-combination-with-keytruda-for-adjuvant-treatment-of-patients-with-resected-high-risk-melanoma/2461890/Merck today announced th
- AI in Action: Perfect Corp. Debuts New Skin Type Detection Technologyhttps://practicaldermatology.com/news/ai-in-action-perfect-corp-debuts-new-skin-type-detection-technology/2461883/
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear
- AD Pipeline Watch: Alphyn Biologics’ Topical AB-101Shows Promise in Phase 2a Studyhttps://practicaldermatology.com/news/ad-pipeline-watch-alphyn-biologics-topical-ab-101shows-promise-in-phase-2a-study/2461852/